For research use only. Not for therapeutic Use.
CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC50s of 0.41 μM and 3.8 μM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for researching atherosclerosis of diabetic patients[1].
CGP-53353 (DAPH-7) (1 μM; 48-96 hours) inhibits glucose-induced cell proliferation in A10 cells[1].
CGP-53353 (1 μM ; 0-48 hours) inhibits the glucose-induced increase and acceleration of DNA synthesis in A10, also blocks the glucose-induced increase of S-phase cell percentage[1].
| Catalog Number | M104290 |
| CAS Number | 145915-60-2 |
| Synonyms | 5,6-bis(4-fluoroanilino)isoindole-1,3-dione |
| Molecular Formula | C20H13F2N3O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H13F2N3O2/c21-11-1-5-13(6-2-11)23-17-9-15-16(20(27)25-19(15)26)10-18(17)24-14-7-3-12(22)4-8-14/h1-10,23-24H,(H,25,26,27) |
| InChIKey | RONQPWQYDRPRGG-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1NC2=C(C=C3C(=C2)C(=O)NC3=O)NC4=CC=C(C=C4)F)F |
| Reference | [1]. Yamamoto M, et al. Acute glucose-induced downregulation of PKC-betaII accelerates cultured VSMC proliferation. Am J Physiol Cell Physiol. 2000;279(3):C587-C595. |
